To conclude, we have demonstrated that DPS is able to classify HR-positive HER2-negative primary operable breast cancer and ≤ 3 positive LN into low or high-risk with similar accuracy and predictive performance as that reported for other risk stratification tools. The gene discussed is ERBB2; the disease is breast carcinoma.